Issues of the current terminology in multiple sclerosis

Close metadata

New terminology used by neurologists with multiple sclerosis (MS). The current use of terms «definite» MS, «MS signs», «retrobulbar neuritis» and «optic neuritis», «relapse and exacerbation, types of MS course, criteria of effectiveness of MS therapy, NEDA, NEP, NEPAD; the classification therapy methods — «escalation», «induction» and therapy of immune reconstitution (TIR), therapy of maintenance/escalation (TME) and discussed.

Keywords:

multiple sclerosis

terminology

diagnostics

treatment

Authors:

Boĭko A.N.

KGBUZ "Krasnoiarskiĭ kraevoĭ Tsentr po profilaktike i bor'be so SPID i infektsionnymi zabolevaniiami"

Scopus AuthorID: 57224826008
ORCID: 0000-0001-6476-6417

Guseva M.R.

Kafedra oftal'mologii pediatricheskogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

Khachanova N.V.

Burdenko Neurosurgical Institute, Moscow, Russia

Gusev E.I.

Kafedra nevrologii i neĭrokhirurgii Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva

RSCI AuthorID: 91278
Scopus AuthorID: 35599379800
ORCID: 0000-0003-0742-6875

List of references:

Gusev EI, Boyko AN, Stoliarov ID. Multiple sclerosis (handbook of terminology). M.: Real Time; 2009. (In Russ.)
Gusev EI, Boyko AN, Stoliarov ID. Multiple sclerosis (handbook of terminology). M.: Zdorovie cheloveka; 2015. (In Russ.)
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017;1474-4422(17):30470-30472. https://doi.org/10.1016/S1474-4422(17)30470-2
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS.Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121-127.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O’Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic Criteria for Multiple Sclerosis: 2005 Revisions to the McDonald Criteria. Ann Neurol. 2005;58:840-846.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JSDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. https://doi.org/10.1002/ana.22366
Schumacher GA, Beebe G, Kibler RF, Kurland RF, Kurland LT, Kurtzke JF, McDowell F, Nagler B, Sibley WA, Tourtellotte WW, Willmon TL. Problems of experimental trials of therapy in multiple sclerosis — report by the Panel on the Evaluation of Experimental Trials of Therapy in Multiple Sclerosis. Ann NY Acad Sci. 1965;122:552-568.
Boyko A, Kesselring J, Paty DW, Siva A, Singhal B, Thompson A, Willoughby E. Multiple sclerosis and public health. Educational and management implications. World Health Organization, Department of Mental Health, Neuroscience and Neurological Disorders. 1999;2:1-11.
Dixon C, Robertson D. To diagnose or not to diagnose? Timing is the question: balancing early diagnosis of multiple sclerosis with misdiagnosis. Expert Rev Neurother. 2018. https://doi.org/10.1080/14737175.2018
Matute-Blanch C, Montalban X, Comabella M. Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. Handb Clin Neurol. 2017;146:67-84. https://doi.org/10.1016/B978-0-12-804279-3.00005-8
Baranova NS, Spirin NN, Fadeeva OA, Shipova EG, Stepanov IO. Lyme disease in patients with multiple sclerosis: clinical, diagnostic and therapeutic features. Zhurnal Nevroogii i Psikhiatrii im. S.S. Korsakova. 2012;112(2-2):64-68. (In Russ.)
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidellines for research protocols. Ann Neurol. 1983;13:227-231.
Dubuisson N, Puentes F, Giovannoni G, Gnanapavan S. Science is 1% inspiration and 99% biomarkers. Mult Scler. 2017;23(11):1442-1452. https://doi.org/10.1177/1352458517709362
Balashov K. Imaging of Central Nervous System Demyelinating Disorders. Continuum (Minneap Minn). 2016;22(5, Neuroimaging):1613-1635.
Chen JJ, Carletti F, Young V, Mckean D, Quaghebeur G. MRI differential diagnosis of suspected multiple sclerosis. Clin Radiol. 2016;71(9):815-827. https://doi.org/10.1016/j.crad.2016.05.010
Bernitsas E, Khan O, Razmjou S, Tselis A, Bao F, Caon C, Millis S, Seraji-Bozorgzad N. Cerebrospinal fluid humoral immunity in the differential diagnosis of multiple sclerosis. PLoS One. 2017;12(7):e0181431. https://doi.org/10.1371/journal.pone.0181431
Stangel M, Fredrikson S, Meinl E, Petzold A, Stüve O, Tumani H. The utility of cerebrospinal fluid analysis in patients with multiple sclerosis. Nat Rev Neurol. 2013;9(5):267-276. https://doi.org/10.1038/nrneurol.2013.41
Nikiforov AS, Guseva MR. Neuroophtalmology. M.: GOETAR-media; 2008. (In Russ.)
Zmurkin VP, Pak SG, Pirogov AI. The Great Medical Encyclopedia. http://бмэ.орг/index.php (In Russ.)
Popova EV, Bryukhov VV, Boyko AN, Krotenkova MV, Konovalova OE, Sharanova SN. Atypical multiple sclerosis — Balo’s concentric sclerosis: two case-reports and a review. Zhurnal Nevroogii i Psikhiatrii im. S.S. Korsakova. 2017;2(2):50-53. (In Russ.) https://doi.org/10.17116/jnevro20171172250-53
Purohit B, Ganewatte E, Schreiner B, Kollias S. Balo’s Concentric Sclerosis with Acute Presentation and Co-Existing Multiple Sclerosis-Typical Lesions on MRI. Case Rep Neurol. 2015;7(1):44-50. https://doi.org/10.1159/000380813
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-286. https://doi.org/10.1212/WNL.0000000000000560
Giovannoni G, Bermel R, Phillips T, Rudick R A brief history of NEDA. Mult Scler Relat Disord. 2018;20:228-230. https://doi.org/10.1016/j.msard.2017.07.011
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS. ORATORIO Clinical Investigators Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220. https://doi.org/10.1056/NEJMoa1606468
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L. OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234. https://doi.org/10.1056/NEJMoa1601277
Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. Mult Scler J Exp Transl Clin. 2018;4(1):2055217318760642. https://doi.org/10.1177/2055217318760642
Montalban X, Wolinsky JS, Kappos L, Hauser SL, Giovannoni G, de Seze J, Bar-Or A, Masterman D, Bernasconi C, Wei W, Garren H, Chin P, Belachew S, Arnold DL. Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients With Primary Progressive Multiple Sclerosis in the ORATORIO Trial. Presented at the 3rd Congress of the European Academy of Neurology (EAN) 24—27 June 2017; Amsterdam: The Netherlands, Platform presentation number PR2086.
Boyko AN, Gusev EI. Current algorithms of diagnosis and treatment of multiple sclerosis based on the individual assessment of the patient Zhurnal Nevroogii i Psikhiatrii im. S.S. Korsakova. 2017;2(2):92-106. (In Russ.) https://doi.org/10.17116/jnevro20171172292-106
Criteria of noneffective and change of the first DMT to second line. Zhurnal Nevroogii i Psikhiatrii im. S.S. Korsakova. 2015;115(8-2):44. (In Russ.)
Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. JAMA Neurol. 2017;74(8):961-969. https://doi.org/10.1001/jamaneurol.2017.0676
Boyko AN, Boyko OV. Cladribine tablets’ potential role as a key example of selective immune reconstitution therapy in multiple sclerosis. Degenerative Neurological and Neuromuscular Disease. 2018;8:35-44. https://doi.org/10.2147/DNND.S161450
Giovannoni G. Cladribine to Treat Relapsing Forms of Multiple Sclerosis. Neurotherapeutics. 2017;14(4):874-887. https://doi.org/10.1007/s13311-017-0573-4

Close metadata